Refsum's Disease—Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder
Refsum's Disease is an inherited metabolic disorder in which a metabolite of branched chain fatty acids accumulates due to lack of appropriate oxidative enzymes. Patients have elevated plasma phytanic acid levels and high concentrations of phytanic acid in a variety of tissues leading to progre...
Saved in:
| Main Authors: | Nimalie J. Perera, Barry Lewis, Huy Tran, Michael Fietz, David R. Sullivan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Obesity |
| Online Access: | http://dx.doi.org/10.1155/2011/482021 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Conventional and advanced MR imaging in infantile Refsum disease
by: Mustafa Kılıç, et al.
Published: (2015-06-01) -
Efficacy of Orlistat on Hyperbilirubinemia in Full Term Neonates
by: M Habibi, et al.
Published: (2024-03-01) -
Ophthalmic Diagnosis and Novel Management of Infantile Refsum Disease with Combination Docosahexaenoic Acid and Cholic Acid
by: Omar Elghawy, et al.
Published: (2021-01-01) -
Taking Orlistat: Predicting Weight Loss over 6 Months
by: Amelia Hollywood, et al.
Published: (2011-01-01) -
LONG-TERM EFFECTS OF ORLISTAT ON EATING BEHAVIOR OF OBESITY PATIENTS
by: E. V. Korneeva
Published: (2015-09-01)